Paper11479219
Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M and 6 others. Cancer Res, 2001. Cited by 185 papers, by iCite.
Cite this record
ConductScience Library. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Papers, record 11479219. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11479219
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Phytogenic | Major topic |
| Leukemia-Lymphoma, Adult T-Cell | Major topic |
| Microtubules | Major topic |
| Tubulin | Major topic |
| Vinblastine | Major topic |
| Vincristine | Major topic |
| Drug Resistance, Neoplasm | |
| Electrophoresis, Gel, Two-Dimensional | |
| Humans | |
| Immunoblotting | |
| Microtubule-Associated Proteins | |
| Models, Molecular | |
| Mutation | |
| Protein Conformation | |
| Protein Processing, Post-Translational | |
| Tumor Cells, Cultured |
Source PubMed
Cited by67
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42085471 | Synthetic data enables human-grade microtubule analysis with foundation models for segmentation. | PLoS Comput Biol | 2026 | https://conductscience.org/library/papers/42085471 | PubMed |
| 41924101 | Sulfonamide derivatives as tubulin polymerization inhibitors: advances in structural mechanisms, structure-activity relationships, and therapeutic potential in cancer treatment. | RSC Adv | 2026 | https://conductscience.org/library/papers/41924101 | PubMed |
| 41019978 | Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines. | Cancer Drug Resist | 2025 | https://conductscience.org/library/papers/41019978 | PubMed |
| 40982350 | New molecular targets in acute leukemias: cytoskeletal regulatory proteins. | Biochem Soc Trans | 2025 | https://conductscience.org/library/papers/40982350 | PubMed |
| 40872698 | Comparative Analysis of Chemotherapy Resistance Mechanisms in Humans and Companion Animals. | Vet Sci | 2025 | https://conductscience.org/library/papers/40872698 | PubMed |
| 40827484 | Tubulin inhibitors: an insight into new strategies to combat leukemia. | Future Med Chem | 2025 | https://conductscience.org/library/papers/40827484 | PubMed |
| 39281032 | Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy. | Biologics | 2024 | https://conductscience.org/library/papers/39281032 | PubMed |
| 38805123 | Tubulin Complexity in Cancer and Metastasis. | Adv Exp Med Biol | 2024 | https://conductscience.org/library/papers/38805123 | PubMed |
| 37920438 | Exploring the mechanism of resistance to vincristine in breast cancer cells using transcriptome sequencing technology. | Oncol Lett | 2023 | https://conductscience.org/library/papers/37920438 | PubMed |
| 36629423 | Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation. | J Enzyme Inhib Med Chem | 2023 | https://conductscience.org/library/papers/36629423 | PubMed |
| 36551566 | Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36551566 | PubMed |
| 36015179 | Design, Synthesis and Biological Investigation of 2-Anilino Triazolopyrimidines as Tubulin Polymerization Inhibitors with Anticancer Activities. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/36015179 | PubMed |
| 35406424 | PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35406424 | PubMed |
| 34995063 | Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes. | Inorg Chem | 2022 | https://conductscience.org/library/papers/34995063 | PubMed |
| 34771642 | Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34771642 | PubMed |
| 32823874 | Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells. | Molecules | 2020 | https://conductscience.org/library/papers/32823874 | PubMed |
| 32636741 | Phytochemicals: Potential Lead Molecules for MDR Reversal. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32636741 | PubMed |
| 32467666 | N-alkylisatin-based microtubule destabilizers bind to the colchicine site on tubulin and retain efficacy in drug resistant acute lymphoblastic leukemia cell lines with less in vitro neurotoxicity. | Cancer Cell Int | 2020 | https://conductscience.org/library/papers/32467666 | PubMed |
| 32252403 | Utilizing Genome-Wide mRNA Profiling to Identify the Cytotoxic Chemotherapeutic Mechanism of Triazoloacridone C-1305 as Direct Microtubule Stabilization. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32252403 | PubMed |
| 32108588 | Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action. | Aging (Albany NY) | 2020 | https://conductscience.org/library/papers/32108588 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MAP4 | 4134 | PubTator's text mining | https://conductscience.org/library/genes/4134 | NCBI Gene |
| RMDN2 | 151393 | PubTator's text mining | https://conductscience.org/library/genes/151393 | NCBI Gene |
| TUBA1B | 10376 | PubTator's text mining | https://conductscience.org/library/genes/10376 | NCBI Gene |
| TUBB3 | 10381 | PubTator's text mining | https://conductscience.org/library/genes/10381 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11479219
GET https://conductscience.org/api/papers/v1/11479219/cited_by?page=2